Abstract: The present disclosure relates to a recombinant oncolytic virus useful for inhibiting the growth of or killing tumor cells. More specifically, the recombinant oncolytic virus contains a heterologous nucleic acid sequence encoding an inflammation suppressive gene including, but not limited to, natural killer cell inhibitor, a chemokine binding protein, and an NF-?B inhibitor. Alternatively, the recombinant oncolytic virus contains a two or more heterologous nucleic acid sequences encoding one or more inflammation suppressive genes including, but not limited to, natural killer cell inhibitor(s), one or more chemokine binding protein(s), and/or one or more NF-?B inhibitor(s). Optionally, a recombinant oncolytic virus may further comprise one or more heterologous viral internal ribosome entry site (IRES) that is neuronally-silent. Such recombinant oncolytic viruses can be used to treat singular tumors or multi-focal tumors, such as those found in hepatocellular carcinoma or other cancers.

Abstract: The present invention relates to compositions comprising compounds which augment activated immune cells, such as T-cells, dendritic cells and natural killer (“NK”) cells, and methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising the administration of said compositions to said subject. In particular, the present invention relates to methods for the treatment or prevention of diseases and disorders, including cancer, inflammatory disorders, and infectious diseases, in a subject comprising administrating to said subject one or more compounds that activate one or more cytokine receptors and one or more compounds that activate one or more co-stimulatory molecules expressed by activated immune cells.

Abstract: The present invention provides a novel method of treating localized solid tumors (metastatic carcinomas, papilloma and warts) in an individual. The method comprises delivering a suicide gene, by way of a recombinant adenoviral vector or other DNA transport system, into the solid tumor. Subsequently, a prodrug, such as the drug ganciclovir, is administered to the individual. The methods of the present invention may used to treat several different types of solid tumors including papillomas, warts, colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain lymphoma and head and neck cancer.

Abstract: Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.

Abstract: Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.

Abstract: The present invention provides a novel method of treating localized solid tumors and papillomas in an individual, as well as metastatic carcinomas. The method comprises delivering a suicide gene, by way of a recombinant adenoviral vector or other DNA transport system, into the tumor, papilloma or wart of an individual. Subsequently, a prodrug, such as the drug gaciclovir.TM., is administered to the individual. Additionally, the present invention provides a method for treating solid tumors, papillomas, warts and metastatic carcinomas, said method comprising introducing both a suicide gene and one or more cytokine genes into the tumor, papilloma or wart of an individual, and subsequently administering a prodrug to the individual. The methods of the present invention may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain lymphoma and head and neck cancer.

Abstract: Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.

Abstract: DNA sequences to mammalian .alpha..sub.1 -antitrypsin are provided which can be used for expression of mammalian .alpha..sub.1 -antitrypsin.This work was supported in part by grants HL16919 and HL27509 from the National Institutes of Health.

Abstract: Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which non-covalently binds to the nucleic acid and covalently links to a surface ligand, nuclear ligand and/or a lysis agent. These may be linked to the binding molecule by spacers.

Abstract: DNA sequences to mammalian .alpha..sub.1 -antitrypsin are provided which can be used for expression of mammalian .alpha..sub.1 -antitrypsin.This work was supported in part by grants HL16919 and HL27509 from the National Institutes of Health.

Abstract: An episomal vector sytem and methods for use in gene therapy in humans and animals. The vector contains a papilloma virus origin of replication, a vector maintenance sequence, a first promoter transcriptionally linked to a therapeutic nucleic acid sequence, a second promoter transcriptionally linked to a papilloma virus E1 gene sequence, and a third promoter transcriptionally linked to a papilloma virus E2 gene sequence or an E1/E2 fusion gene. The vector is capable of episomal replication in human or animal cells.

Abstract: The present invention provides a novel method of treating localized solid tumors and papilloma in an individual. The method comprises introducing a recombinant adenoviral vector containing the herpes simplex virus-thymidine kinase gene. Subsequently, a prodrug, such as the drug ganciclovir, is administered to the individual. The methods of the present invention may be used to treat several different types of cancers and papillomas, including colon carcinoma, prostate cancer, breast cancer, lung cancer, melanoma, hepatoma, brain and head and neck cancer.

Abstract: DNA sequences to mammalian .alpha..sub.1 -antitrypsin are provided which can be used for expression of mammalian .alpha..sub.1 -antitrypsin.

Abstract: Disclosed is a method for detection of the mutation in phenylalanine hydroxylase genes. This method can be used for the detection of PKU affected, PKU heterozygotes and normals. Also disclosed are oligonucleotides synthesized to detect the first mutations identified in the human phenylalanine hydroxylase gene. The synthesized probes have base pair mismatches with genomic DNA to facilitate the diagnosis of normal and mutant phenylalanine hydroxylase genes. A simple method for detection of the genetic trait, PKU, without obtaining a previous family history of PKU is provided.

Abstract: Methods are provided for the formation of dental enamel crystals in biosynthetic matrix form by the nucleation of calcium solutions with enamel proteins and for the use of such enamel crystals as restorative material.